Glenmark Pharmaceuticals has secured a significant approval from the US FDA for its inhaler fluticasone propionate. This marks a key step i...

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three...

Ryaltris is a fixed-dose combination of olopatadine, an antihistamine and mometasone furoate, a corticosteroid to treat the symptoms of all...

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...

Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...

The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastroi...

Glenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...

Ryaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...

The Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...

Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost fo...

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 1...

Glenmark Specialty, a Switzerland-based unit of the company, has entered into an exclusive licensing agreement with the Menarini Group for ...

Glenmark is targeting a consolidated revenue growth of 12-15 per cent over the next 3-5 years.

Glenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.

According to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...

Glenmark Pharmaceuticals aims to keep growing its base business by 18-20 per cent per annum over the next ten years.

As per the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries